Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival

(2015) Laurent Muller et al.   OncoImmunology

Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!

(2014) M. G. Castro et al.   CLINICAL CANCER RESEARCH

Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma

(2014) Robert A Fenstermaker et al.   Expert Review of Vaccines

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

(2014) L. Shen et al.   Cancer Immunology Research

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients

(2011) Melanie Widenmeyer et al.   INTERNATIONAL JOURNAL OF CANCER

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Antitumor cytotoxic T-cell response induced by a survivin peptide mimic

(2010) Michael J. Ciesielski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers

(2008) J Nakano et al.   BRITISH JOURNAL OF CANCER

Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma

(2008) Michael J. Ciesielski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: Quantitative and qualitative effects of CD4+ T cells

(2008) Eun-Kyung Kim et al.   VACCINE